187 related articles for article (PubMed ID: 24052127)
1. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer.
Rojas-Martínez A; Manzanera AG; Sukin SW; Esteban-María J; González-Guerrero JF; Gomez-Guerra L; Garza-Guajardo R; Flores-Gutiérrez JP; Elizondo Riojas G; Delgado-Enciso I; Ortiz-López R; Aguilar LK; Butler EB; Barrera-Saldaña HA; Aguilar-Cordova E
Cancer Gene Ther; 2013 Nov; 20(11):642-9. PubMed ID: 24052127
[TBL] [Abstract][Full Text] [Related]
2. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.
Herman JR; Adler HL; Aguilar-Cordova E; Rojas-Martinez A; Woo S; Timme TL; Wheeler TM; Thompson TC; Scardino PT
Hum Gene Ther; 1999 May; 10(7):1239-49. PubMed ID: 10340555
[TBL] [Abstract][Full Text] [Related]
3. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
[TBL] [Abstract][Full Text] [Related]
4. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy.
Sonpavde G; Thompson TC; Jain RK; Ayala GE; Kurosaka S; Edamura K; Tabata K; Ren C; Goltsov AA; Mims MP; Hayes TG; Ittmann MM; Wheeler TM; Gee A; Miles BJ; Kadmon D
Clin Cancer Res; 2011 Nov; 17(22):7174-82. PubMed ID: 21933889
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.
Freytag SO; Stricker H; Pegg J; Paielli D; Pradhan DG; Peabody J; DePeralta-Venturina M; Xia X; Brown S; Lu M; Kim JH
Cancer Res; 2003 Nov; 63(21):7497-506. PubMed ID: 14612551
[TBL] [Abstract][Full Text] [Related]
6. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy.
Nasu Y; Saika T; Ebara S; Kusaka N; Kaku H; Abarzua F; Manabe D; Thompson TC; Kumon H
Mol Ther; 2007 Apr; 15(4):834-40. PubMed ID: 17327829
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma.
Kieran MW; Goumnerova L; Manley P; Chi SN; Marcus KJ; Manzanera AG; Polanco MLS; Guzik BW; Aguilar-Cordova E; Diaz-Montero CM; DiPatri AJ; Tomita T; Lulla R; Greenspan L; Aguilar LK; Goldman S
Neuro Oncol; 2019 Mar; 21(4):537-546. PubMed ID: 30883662
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
9. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.
Aguilar LK; Shirley LA; Chung VM; Marsh CL; Walker J; Coyle W; Marx H; Bekaii-Saab T; Lesinski GB; Swanson B; Sanchez D; Manzanera AG; Aguilar-Cordova E; Bloomston M
Cancer Immunol Immunother; 2015 Jun; 64(6):727-36. PubMed ID: 25795132
[TBL] [Abstract][Full Text] [Related]
10. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo.
Tjuvajev JG; Chen SH; Joshi A; Joshi R; Guo ZS; Balatoni J; Ballon D; Koutcher J; Finn R; Woo SL; Blasberg RG
Cancer Res; 1999 Oct; 59(20):5186-93. PubMed ID: 10537296
[TBL] [Abstract][Full Text] [Related]
11. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Chiocca EA; Aguilar LK; Bell SD; Kaur B; Hardcastle J; Cavaliere R; McGregor J; Lo S; Ray-Chaudhuri A; Chakravarti A; Grecula J; Newton H; Harris KS; Grossman RG; Trask TW; Baskin DS; Monterroso C; Manzanera AG; Aguilar-Cordova E; New PZ
J Clin Oncol; 2011 Sep; 29(27):3611-9. PubMed ID: 21844505
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus vector carrying REIC/DKK-3 gene: neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy.
Kumon H; Ariyoshi Y; Sasaki K; Sadahira T; Araki M; Ebara S; Yanai H; Watanabe M; Nasu Y
Cancer Gene Ther; 2016 Nov; 23(11):400-409. PubMed ID: 27767086
[TBL] [Abstract][Full Text] [Related]
13. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors.
Xu F; Li S; Li XL; Guo Y; Zou BY; Xu R; Liao H; Zhao HY; Zhang Y; Guan ZZ; Zhang L
Cancer Gene Ther; 2009 Sep; 16(9):723-30. PubMed ID: 19363470
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy.
Miles BJ; Shalev M; Aguilar-Cordova E; Timme TL; Lee HM; Yang G; Adler HL; Kernen K; Pramudji CK; Satoh T; Gdor Y; Ren C; Ayala G; Wheeler TM; Butler EB; Kadmon D; Thompson TC
Hum Gene Ther; 2001 Nov; 12(16):1955-67. PubMed ID: 11686937
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity.
Predina JD; Haas AR; Martinez M; O'Brien S; Moon EK; Woodruff P; Stadanlick J; Corbett C; Frenzel-Sulyok L; Bryski MG; Eruslanov E; Deshpande C; Langer C; Aguilar LK; Guzik BW; Manzanera AG; Aguilar-Cordova E; Singhal S; Albelda SM
Mol Ther; 2021 Feb; 29(2):658-670. PubMed ID: 33160076
[TBL] [Abstract][Full Text] [Related]
16. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice.
Timme TL; Hall SJ; Barrios R; Woo SL; Aguilar-Cordova E; Thompson TC
Cancer Gene Ther; 1998; 5(2):74-82. PubMed ID: 9570298
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer.
Hall SJ; Mutchnik SE; Chen SH; Woo SL; Thompson TC
Int J Cancer; 1997 Jan; 70(2):183-7. PubMed ID: 9009158
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer.
Shirakawa T; Terao S; Hinata N; Tanaka K; Takenaka A; Hara I; Sugimura K; Matsuo M; Hamada K; Fuji K; Okegawa T; Higashihara E; Gardner TA; Kao C; Chung LW; Kamidono S; Fujisawa M; Gotoh A
Hum Gene Ther; 2007 Dec; 18(12):1225-32. PubMed ID: 18021019
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer.
Kubo H; Gardner TA; Wada Y; Koeneman KS; Gotoh A; Yang L; Kao C; Lim SD; Amin MB; Yang H; Black ME; Matsubara S; Nakagawa M; Gillenwater JY; Zhau HE; Chung LW
Hum Gene Ther; 2003 Feb; 14(3):227-41. PubMed ID: 12639303
[TBL] [Abstract][Full Text] [Related]
20. Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter.
Ahn M; Lee SJ; Li X; Jiménez JA; Zhang YP; Bae KH; Mohammadi Y; Kao C; Gardner TA
Cancer Gene Ther; 2009 Jan; 16(1):73-82. PubMed ID: 18772902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]